Synchron Has Been Given The Green Light To Conduct Clinical Trials For Its Brain Implant Chip

Advertisement

Neuralink has been working on providing a relay in connecting the digital world to the human brain. This technology will render the need of having any mobile phone, computers, or other digital devices futile. Other companies like Synchron are working on the same goal as well and are considered a direct rival for Neuralink.

 A direct chip will be made to connect with the head that will lead to a connection to the brain. Everything will be then available to the person. Neuralink is owned by none other than Elon Musk who is a pioneer in putting forward smart, advanced, modern, and innovative technology, but now companies like Synchron have also joined the fray.

Synchron has been working on making the chips and making wireless communication seamless. It is basically a brain data transfer company that makes implantable brain-computer interfaces (BCI). The Food and Drug Administration (FDA) has given it permission to start the trials on humans. These clinical trials will leave Neuralink behind.

The company intends to plant the device, Stentrode™ in patients who are paralyzed and cannot move their limbs. The device will allow them to use digital screens without using their fingertips. The device will allow the screens to be directed by the thoughts generated in the brain of the patient. This is like a matchstick. Another implant will aid the process which will be a very small cable in the chest.

The most intriguing factor of the device is that it does not need brain surgery to be inserted into the body. It will be introduced into the body through a blood vessel in the neck. It will be similar to the insertion of heart stents.

The clinical trials will be monitored in Mount Sinai Hospital, New York on 6 patients. It is like the testing of phase 2 of testing a drug. The report is published in the Journal of NeuroInterventional Surgery. Dr. J Mocco, the chief medical officer at Synchron and a professor of neurosurgery at Mount Sinai Health System in New York states that it will be commercially available in 3 to 4 years.

Advertisement

Leave a Reply

Your email address will not be published. Required fields are marked *